Lupin Receives US FDA Tentative Approval for Letermovir Tablets
Overview
Global pharma major Lupin Limited announced that it has received a tentative approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application for letermovir tablets, 240 mg and 480 mg, to market a generic equivalent of Prevymis tablets, 240 mg and 480 mg, of Merck Sharp & Dohme LLC. This product will be manufactured at Lupin’s Nagpur facility in India. Letermovir tablets
Letermovir tablets, 240 mg and 480 mg are indicated for prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant.
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!